Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn

Lin Yao, Zhan-rong Li, Wen-ru Su, Yong-ping Li, Miao-li Lin, Wen-xin Zhang, Yi Liu, Qian Wan, Dan Liang, Lin Yao, Zhan-rong Li, Wen-ru Su, Yong-ping Li, Miao-li Lin, Wen-xin Zhang, Yi Liu, Qian Wan, Dan Liang

Abstract

The aim of this study was to investigate the effects of subconjunctivally administered mesenchymal stem cells (MSCs) on corneal wound healing in the acute stage of an alkali burn. A corneal alkali burn model was generated by placing a piece of 3-mm diameter filter paper soaked in NaOH on the right eye of 48 Sprague-Dawley female rats. 24 rats were administered a subconjunctival injection of a suspension of 2×10(6) MSCs in 0.1 ml phosphate-buffered saline (PBS) on day 0 and day 3 after the corneal alkali burn. The other 24 rats were administered a subconjunctival injection of an equal amount of PBS as a control. Deficiencies of the corneal epithelium and the area of corneal neovascularization (CNV) were evaluated on days 3 and 7 after the corneal alkali burn. Infiltrated CD68(+) cells were detected by immunofluorescence staining. The mRNA expression levels of macrophage inflammatory protein-1 alpha (MIP-1α), tumor necrosis factor-alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1) and vascular endothelial growth factor (VEGF) were analyzed using real-time polymerase chain reaction (real-time PCR). In addition, VEGF protein levels were analyzed using an enzyme-linked immunosorbent assay (ELISA). MSCs significantly enhanced the recovery of the corneal epithelium and decreased the CNV area compared with the control group. On day 7, the quantity of infiltrated CD68(+) cells was significantly lower in the MSC group and the mRNA levels of MIP-1α, TNF-α, and VEGF and the protein levels of VEGF were also down-regulated. However, the expression of MCP-1 was not different between the two groups. Our results suggest that subconjunctival injection of MSCs significantly accelerates corneal wound healing, attenuates inflammation and reduces CNV in alkaline-burned corneas; these effects were found to be related to a reduction of infiltrated CD68(+) cells and the down-regulation of MIP-1α, TNF-α and VEGF.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Characterization of MSCs.
Figure 1. Characterization of MSCs.
(A) Flow cytometry analysis of mesenchymal stem cells (MSCs). Expression of CD29, CD44 and CD90 in isolated MSCs. MSCs did not express CD34, CD45 or CD11b. (B) Osteogenic differentiation (Magnification, ×100). (C) adipogenic differentiation (Magnification, ×400).
Figure 2. Effects of MSCs on epithelial…
Figure 2. Effects of MSCs on epithelial recovery.
(A–D) Representative images of fluorescein staining of the cornea on day 3 and day 7 after the alkali burn. Control group on day 3 (A) and day 7 (B); MSC group on day 3 (C) and day 7 (D). (E) Statistical analysis of number of the fluorescein staining of the cornea on day 3 and day 7. On both day 3 and day 7, the quantity of fluorescein staining of the cornea was significantly lower in the MSC group compared with the control group.
Figure 3. Anti-inflammatory effects of MSCs in…
Figure 3. Anti-inflammatory effects of MSCs in the cornea.
(A B) H-E staining on day 7 (Magnification, ×200); (C D) Immunofluorescence staining of CD68 on day 7 (Magnification, ×400); (A C) Control group; (B D) MSC group. (E) Statistical analysis of infiltrated cells and infiltrated CD68+ cells in the corneal stroma on day 7 after the corneal alkali burn. (F–H) Statistical analysis of real-time PCR results of MIP-1α (F), MCP-1 (G) and TNF-α (H) on day 7 (* p<0.05; ** p<0.01; *** p<0.001).
Figure 4. Effects of MSCs on CNV.
Figure 4. Effects of MSCs on CNV.
(A–D) Representative images of CNV on day 3 and day 7 after the alkali burn. Control group on day 3 (A) and day 7 (B); MSC group on day 3 (C) and day 7 (D). (E) Area of CNV on day 3 and day 7 in both groups. (F G) Statistical analysis of real-time PCR and ELISA results of VEGF on day 7 (* p<0.05; ** p<0.01).
Figure 5. Engraftment of MSCs.
Figure 5. Engraftment of MSCs.
(A) No DiI-labeled MSCs were detected in the cornea on day 7 after the corneal alkali burn. (B) A large number of DiI-labeled MSCs were detected in the subconjunctival tissues on day 7 after the corneal alkali burn (Magnification, ×400).

References

    1. Wagoner MD. Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmol. 1997;41:275–313.
    1. Brodovsky SC, McCarty CA, Snibson G, Loughnan M, Sullivan L, et al. Management of alkali burns: an 11-year retrospective review. Ophthalmology. 2000;107:1829–1835.
    1. Kuo IC. Corneal wound healing. Curr Opin Ophthalmol. 2004;15:311–315.
    1. Adamis AP, Aiello LP, D'Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis. 1999;3:9–14.
    1. He J, Bazan NG, Bazan HE. Alkali-induced corneal stromal melting prevention by a novel platelet-activating factor receptor antagonist. Arch Ophthalmol. 2006;124:70–78.
    1. Zannettino AC, Paton S, Arthur A, Khor F, Itescu S, et al. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J Cell Physiol. 2008;214:413–421.
    1. Hoogduijin MJ, Crop MJ, Peeters AM, Van Osch GJ, Balk AH, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev. 2007;16:597–604.
    1. Oh W, Kim DS, Yang YS, Lee JK. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Cell Immunol. 2008;25:116–123.
    1. Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol. 2009;183:7787–7798.
    1. Zhang QZ, Su WR, Shi SH, Wilder-Smith P, Xiang AP, et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells. 2010;28:1856–1868.
    1. Su WR, Zhang QZ, Shi SH, Nguyen AL, Le AD. Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E(2) -dependent mechanisms. Stem Cells. 2011;29:1849–1860.
    1. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499–3506.
    1. Zhao S, Wehner R, Bornhauser M, Wassmuth R, Bachmann M, et al. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 2010;19:607–614.
    1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–736.
    1. Oh JY, Kim MK, Shin MS, Lee HJ, Ko JH, et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cell. 2008;26:1047–1055.
    1. Ma Y, Xu Y, Xiao Z, Yang W, Zhang C, et al. Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. Stem Cells. 2005;24:315–321.
    1. Ye J, Yao K, Kim JC. Mesenchymal stem cell transplantation in a rabbit corneal alkali burn model: engraftment and involvement in wound healing. Eye (Lond) 2006;20:482–490.
    1. Jiang TS, Cai L, Ji WY, Hui YN, Wang YS, et al. Reconstruction of the corneal epithelium with induced marrow mesenchymal stem cells in rats. Mol Vis. 2010;16:1304–1316.
    1. Popp FC, Slowik P, Eggenhofer E, Renner P, Lang SA, et al. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells. 2007;25:639–645.
    1. Su W, Li Z, Lin M, Li Y, He Z, et al. The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats. Graefes Arch Clin Exp Ophthalmol. 2011;249:421–427.
    1. Wilson SE, Mohan RR, Mohan RR, Ambrosio R, Jr, Hong J. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res. 2001;20:625–637.
    1. Choi JA, Choi JS, Joo CK. Effects of amniotic membrane suspension in the rat alkali burn model. Mol Vis. 2011;17:404–412.
    1. DiPietro LA, Burdick M, Low QE, Kunkel SL, Strieter RM. MIP-1alpha as a critical macrophage chemoattractant in murine wound repair. J Clin Invest. 1998;15:1693–1698.
    1. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One. 2010;5:e9252.
    1. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–1822.
    1. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011;29:913–919.
    1. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722–3729.
    1. Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol. 2005;33:928–934.
    1. Shi W, Wang T, Gao H, Xie L. Management of severe ocular burns with symblepharon. Graefes Arch Clin Exp Ophthalmol. 2009;247:101–106.
    1. Fogla R, Padmanabhan P. Deep anterior lamellar keratoplasty combined with autologous limbal stem cell transplantation in unilateral severe chemical injury. Cornea. 2005;24:421–425.
    1. Borderie V, Touzeau O, Bourcier T, Allouch C, Scheer S, et al. Treatment of the sequelae of ocular burns using limbal transplantation. J Fr Ophtalmol. 2003;26:710–716.
    1. Kuckelkorn R, Schrage N, Keller G, Redbrake C. Emergency treatment of chemical and thermal eye burns. Acta Ophthalmol Scand. 2002;80:4–10.
    1. Fish R, Davidson RS. Management of ocular thermal and chemical injuries, including amniotic membrane therapy. Curr Opin Ophthalmol. 2010;21:317–321.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera